DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
ANGO logo

AngioDynamics, Inc. Stock Price

NasdaqGS:ANGO Community·US$639.0m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

ANGO Share Price Performance

US$15.37
4.36 (39.60%)
​
US$18.25
Fair Value
US$15.37
4.36 (39.60%)
15.8% undervalued intrinsic discount
US$18.25
Fair Value
Price US$15.37
AnalystConsensusTarget US$18.25
AnalystHighTarget US$24.00
AnalystLowTarget US$16.00
Thu, 4 Sep 25
Fair ValueUS$18.25
Share Pricen/a

ANGO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$18.25 15.8% undervalued intrinsic discount

Rising Demand For Minimally Invasive Care Will Expand Med Tech

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$24 36.0% undervalued intrinsic discount

AlphaVac And NanoKnife Will Transform Global Minimally Invasive Care

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$16 3.9% undervalued intrinsic discount

Rising Tariffs Will Pressure Margins But Modest Recovery Will Follow

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
ANGO logo
AngioDynamics
3.9% undervalued intrinsic discount

Rising Tariffs Will Pressure Margins But Modest Recovery Will Follow

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Published 6 Sep 2025
Read Narrative
ANGO logo
AngioDynamics
36.0% undervalued intrinsic discount

AlphaVac And NanoKnife Will Transform Global Minimally Invasive Care

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Published 4 Sep 2025
Read Narrative
ANGO logo
AngioDynamics
15.8% undervalued intrinsic discount

Rising Demand For Minimally Invasive Care Will Expand Med Tech

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 30 May 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
ANGO logo

Rising Tariffs Will Pressure Margins But Modest Recovery Will Follow

Fair Value: US$16 3.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
ANGO logo

AlphaVac And NanoKnife Will Transform Global Minimally Invasive Care

Fair Value: US$24 36.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
ANGO logo

Rising Demand For Minimally Invasive Care Will Expand Med Tech

Fair Value: US$18.25 15.8% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
3 Rewards
View Full Analysis

AngioDynamics, Inc. Key Details

US$320.2m

Revenue

US$145.3m

Cost of Revenue

US$174.9m

Gross Profit

US$211.6m

Other Expenses

-US$36.7m

Earnings

Last Reported Earnings
May 31, 2026
Next Reporting Earnings
n/a
-0.89
54.62%
-11.48%
3.4%
View Full Analysis

About ANGO

Founded
1988
Employees
632
CEO
James Clemmer
WebsiteView website
www.angiodynamics.com

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers’ off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which include angiographic catheters, guidewires, drainage catheters, and micropuncture kits for use in invasive procedures. In addition, the company provides total abscession drainage catheters for multi-purpose/general and biliary configurations, and nephrostomy options; mini stick MAX Coaxial microintroducer kits and micro-introducer kits; ports; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

Recent ANGO News & Updates

Seeking Alpha • Jul 16

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

Summary AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum. But I downgrade to a hold as I see limited upside after the recent rally, premium valuation, and execution risk. Read the full article on Seeking Alpha

Recent updates

No updates

AngioDynamics, Inc. Competitors

NEO logo

NeoGenomics

Symbol: NasdaqCM:NEO
Market cap: US$2.4b
CLOV logo

Clover Health Investments

Symbol: NasdaqGS:CLOV
Market cap: US$2.4b
ASST logo

Strive

Symbol: NasdaqGM:ASST
Market cap: US$2.3b
ADUS logo

Addus HomeCare

Symbol: NasdaqGS:ADUS
Market cap: US$2.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide